Rationale: Large airway dimensions on computed tomography (CT) have been associated with lung function, symptoms, and exacerbations in chronic obstructive pulmonary disease (COPD), as well as with symptoms in smokers with preserved spirometry. Their prognostic significance in persons without lung disease remains undefined.
Chronic lower respiratory diseases (CLRDs) are a leading cause of hospitalization and the fourth leading cause of death in the United States (1, 2) , despite large reductions in cigarette smoking and other risk factors (3) . The Centers for Disease Control and Prevention defines CLRD to include chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, and asthma (2)-diseases characterized by chronic or intermittent airflow limitation that result, to varying extents, from alterations in the airways.
Whereas spirometry provides a global measure of airway physiology and is the gold standard diagnostic test for COPD, computed tomography (CT) can precisely characterize the dimensions of the proximal airways. Alterations in large airway structure on CT correlate with pathological changes of smooth muscle hypertrophy, inflammation, and subepithelial fibrosis (4). Pi10, the average wall thickness for a hypothetical airway of 10-mm lumen perimeter on CT, has been associated in patients with COPD with chronic bronchitis (5) , greater symptoms (6), increased exacerbations, and increased mortality in the context of higher emphysema (7) (8) (9) . Pi10 has also been associated with respiratory symptoms among smokers with preserved lung function (10) . Pi10 increases across GOLD (Global Initiative for Chronic Obstructive Lung Disease) stages in COPD, and spatial matching of airways suggests that this is due to decreased airway wall area coupled with even greater decrements in airway lumen size, resulting in greater wall area percentage and Pi10 in COPD (11) .
In healthy adults without CLRD, the prognostic significance of large airway dimensions on CT remains undefined. We therefore examined whether Pi10-and secondarily its component measures of airway wall thickness (AWT) and lumen size-were associated with accelerated lung function decline, incident spirometrically defined COPD, and risk of first hospitalization or mortality due to CLRD, in a populationbased study cohort free of clinical CLRD at baseline. Some results of this study were previously published in the form of an abstract (12) .
Methods

Design and Sample
The Multi-Ethnic Study of Atherosclerosis (MESA) enrolled 6,814 participants ages 45-84 years who self-reported white, African American, Hispanic, or Asian race/ethnicity in 2000-2002 ( Figure 1 ). Exclusion criteria were history of clinical cardiovascular disease, weight greater than 136 kg, and impediments to long-term participation. Participants were recruited from Forsyth County, North Carolina; northern Manhattan and the Bronx, New York; Baltimore City and Baltimore County, Maryland; St. Paul, Minnesota; Chicago, Illinois; and Los Angeles, California (13) . The MESA Air Study recruited 257 additional participants in 2006-2007 using identical inclusion criteria (14) . For the present study, we excluded participants with prevalent clinical CLRD, defined as selfreport of a prior physician diagnosis of CLRD, or current use of inhaled corticosteroids or bronchodilators.
Large Airway Dimensions on CT
All participants underwent low-dose cardiac CT at baseline in 2000-2002 on one of three types of scanner: the Imatron electron beam computed tomography (EBT) scanner, the Siemens multidetector computed tomography (MDCT) scanner, or the GE Healthcare Life Sciences MDCT scanner (15) . For each participant, two cardiac-gated computed tomographic scans were obtained following a standardized protocol at full inspiration that reduced cardiac-related motion artifact in the left lower lobe. These scans included approximately 66% of the lung from carina to lung bases (16) and were reconstructed at approximately 3-mm increments. Of paired scans, the scan with the greater volume of lung air was used, except in cases of discordant quality scores, when the higher-quality scan was used.
Airway dimensions were assessed in the lower lobes using a simple algorithm applicable to clinical low-dose chest computed tomographic scans, which are typically reconstructed at 0.7-to 2.5-mm increments (17) . Airways scanned perpendicular to the airway long axis (i.e., airway lumen was approximately circular) were measured in two dimensions using a modified full-width half-maximum principle with dedicated software (PASS; NCSS, Inc.), as previously described (18) , to define outer and inner airway wall borders.
Pi10 was calculated by creating individual regression plots for each participant of the square root of the wall area against the corresponding internal perimeter for each measured airway in the lower lobes (19) (20) (21) (22) . Airways with internal perimeter less than or equal to 6 mm were excluded from Pi10 calculations; furthermore, Pi10 was not calculated in participants with fewer than six eligible airway measures (18) . Among participants with valid Pi10, the distribution for the number of airways measured per participant was rightward skewed (average, 8.6; range, 6-41).
The Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study is funded by National Institutes of Health (NIH) grants R01-HL077612 and R01-HL075476. Additional funding is provided by NIH grants R21-HL129924 (E.C.O.), K23-HL130627 (E.C.O.), R01-HL130506 (B.M.S.), and R01-HL093081 (R.G.B.). MESA also was supported by NIH contracts N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165,  N01-HC-95166, N01-HC-95167, N01-HC-95168 , and N01-HC-95169 from the National Heart, Lung, and Blood Institute and by grants UL1-TR-000040 and UL1-RR-025005 from the National Center for Research Resources. This publication was also developed under a STAR research assistance agreement (RD831697 [MESA Air]) awarded by the U.S. Environmental Protection Agency (EPA). It was not formally reviewed by the EPA. The views expressed in this document are solely those of the authors, and the EPA does not endorse any products or commercial services mentioned in this publication.
Author Contributions: E.C.O.: literature search, funding, study design, data analysis, data interpretation, drafting of the manuscript, and preparation of tables and figures; B.M.S., R.K., K.M.D., and J.E.S.: study design, data interpretation, and manuscript review; E.A.H.: study design, data collection, data interpretation, and manuscript review; J.D.K., A.W.M., J.I.R., E.D.M., D.R.J., G.L.B., A.R.F., and K.W.: study design, data collection, data interpretation, and manuscript review; J.N.N.: data collection, data interpretation, and manuscript review; and R.G.B.: study design, funding, data collection, data interpretation, and drafting and review of the manuscript. The corresponding author had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors meet the International Committee of Medical Journal Editors criteria for authorship, all having made substantial contributions to study conception, design, and/or data collection; interpretation of data; drafting and/or critical revision of the manuscript; and final manuscript review. All coauthors agree to be accountable for all aspects of the work and will ensure that any questions regarding the accuracy or integrity of any part of the work are appropriately investigated and resolved.
ORIGINAL RESEARCH
In addition to deriving Pi10, direct measurements of airway lumen diameter and AWT were undertaken in a single segmental lower lobe (LB10 or RB10) airway for each participant, an approach that was validated in a subset of MESA participants (18 (23) . All these participants were selected for spirometry at 5-year follow-up examination in 2010-2012 using the same protocol and equipment, when those with prebronchodilator forced expiratory volume in 1 second (FEV 1 )/ forced vital capacity (FVC) less than 0.70 or less than the lower limit of normal were selected for post-bronchodilator measurements. Spirometry was conducted using an automated dry rolling seal spirometer according to American Thoracic Society guidelines; examinations with less than two acceptable measures repeatable within 200 ml were excluded (24) .
For lung function analyses, the sample was restricted to participants with valid spirometry at both examinations and without airflow limitation on initial spirometry, defined as prebronchodilator FEV 1 /FVC less than 0.70 (25) . Incident COPD was defined as post-bronchodilator FEV 1 /FVC less than 0.70 in 2010-2012 (25) . For sensitivity analyses, a lower limit of normal threshold (26) was used to define incident prebronchodilator airflow limitation at 2010-2012 examination.
Incident CLRD Events
Interviewers contacted participants or family members every 9-12 months from study baseline through December 2014 to ascertain all hospitalizations and deaths. The National Death Index was reviewed to ensure complete follow-up for mortality.
Hospitalization or mortality due to CLRD were defined following algorithms previously validated in this cohort (27, 28) as events with one of the following International Classification of Diseases (ICD) codes listed as the primary discharge diagnosis or as the underlying cause of death: asthma (ICD-9 code 493, ICD-10 codes J45-J46), COPD (ICD-9 code 496, ICD-10 code J44), chronic bronchitis (ICD-9 codes 490-491, ICD-10 codes J40-J42), or emphysema (ICD-9 code 492, ICD-10 code J43). COPD hospitalization/ mortality were defined by ICD codes for COPD, chronic bronchitis, or emphysema.
Covariates
Age, sex, race/ethnicity, education, secondhand smoke, and tobacco use were self-reported at baseline. Never smokers were defined by lifetime smoking less than 100 cigarettes, and current smokers were defined by cigarette use within the past 30 days. Urinary cotinine was measured at baseline, and 78 participants (2%) who denied current smoking but had cotinine greater than 100 ng/ml were reclassified as current smokers. Pack-years were calculated as (cigarettes per day/20) 3 years smoked. Height and weight were measured using standard techniques. Percent emphysema was defined as (lung voxels less than 2950 Hounsfield units/total imaged lung voxels 3 100) on cardiac CT, as previously 
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described (16) . Long-term outdoor concentrations of particulate matter less than or equal to 2.5 mm in aerodynamic diameter were estimated at each participant's home for the 2 years preceding baseline examination using spatiotemporal models (29) . Genotyping was performed using the Affymetrix Genome-Wide Human SNP Array 6.0 (Thermo Fisher Scientific), with 897,981 single-nucleotide polymorphisms (SNPs) passing study-specific quality control, and imputation of an additional approximately 2 million SNPs via 1000 Genomes imputation (phase 3, version 5, imputationserver.sph.umich.edu/index. html) and the Haplotype Reference Consortium (http://www.haplotypereference-consortium.org/). Genotype data were used to estimate principal components of genetic ancestry (30, 31) and weighted genetic risk scores for COPD (32) .
Statistical Approach
Baseline participant characteristics were tabulated by Pi10 quartile. Unadjusted comparisons were tested by one-way analysis of variance or Fisher's exact test.
For regression analyses, Pi10 was logarithmically transformed for normality. Measures of association were reported per standard deviation (SD) of logarithmically transformed Pi10. Associations with change in FEV 1 were tested in random intercept mixed models (33) . Logistic regression was used to test associations with incident COPD at 5-year follow-up. Cox proportional hazards models were used to calculate hazard ratios (HRs) for incident CLRD hospitalization/mortality, with time to event defined as days between baseline examination and event date or last followup. The proportional hazards assumption was checked via residual plots. Analyses were repeated for hospitalization/mortality due to asthma versus COPD. Linearity of associations between untransformed Pi10 and CLRD hospitalization/mortality was tested in fully adjusted generalized additive models. Competing risks regression was performed as a sensitivity analysis (34) .
Models were adjusted for a priori confounders and precision variables. The partially adjusted model included age, sex, race/ethnicity, and body mass index. The fully adjusted model also included smoking status, pack-years, CT scanner type, voxel size, and percent emphysema. Extended models, which were limited to participants with genotyping, added adjustment for principal components of genetic ancestry in place of self-reported race/ethnicity, COPD genetic risk score, and initial FEV 1 percent predicted (26) . The impact of further adjustment for education, secondhand smoke, and particulate matter less than or equal to 2.5 mm in aerodynamic diameter was tested in sensitivity analyses. Effect measure modification was assessed via multiplicative interaction terms and stratified models. AWT and lumen diameter were logarithmically transformed, and their associations with the outcomes were tested in fully adjusted models including both AWT and lumen diameter. Analyses were conducted by using SAS version 9.3 software (SAS Institute) or R software (R Foundation for Statistical Computing).
Results
Baseline Characteristics
Of 6,814 total MESA participants, 470 (6.9%) were missing valid airway measurements, and an additional 315 (4.6%) had clinical CLRD at baseline (Figure 1 ). The mean age of the remaining 6,029 participants was 62 years at enrollment. Forty-eight percent were male, 39% were white, 28% were African American, 22% were Hispanic/Latino American, and 12% were Asian American. Forty-six percent were never smokers, 40% were former smokers, and 14% were current smokers; among smokers, 42% reported a history of less than 10 pack-years. Higher Pi10 quartiles demonstrated greater proportions of men, current smokers, Hispanic/Latino Americans, and Asian Americans, and participants in these quartiles were more likely to have been examined on EBT scanners (Table 1) . Participants in higher Pi10 quartiles had lesser initial FEV 1 percent predicted, greater FEV 1 decline, and higher incidence of COPD at follow-up (Table 2 ). In fully adjusted analyses, per SD increment in Pi10, there was, on average, 2.47 ml greater decline in FEV 1 per year (95% confidence interval [CI], 0.66, 4.28; P = 0.008) ( Table 3 ). This was equivalent to a 9% greater decline compared with the overall average and comparable to the effect estimate for former smoking (4.40 ml/yr). Per SD of Pi10, the adjusted odds of incident spirometry-defined COPD were 1.87-fold higher (95% CI, 1.26, 2.78; P = 0.002) ( Table 3) .
Statistical evidence for effect modification by smoking status was absent (P = 0.93), although in stratified analyses, the magnitude of the effect estimates increased with pack-years of smoking, and it was markedly higher in participants with 30 or more pack-years, who could qualify for lung cancer screening CT (27.92 ml/SD; 95% CI, 213.59, 22.25). Associations were consistent across strata of other potential effect modifiers, including sex and race/ ethnicity, and scanner type ( Figure 2) ; however, site-stratified analyses showed inconsistent associations in the small number of participants scanned on a GE Healthcare Life Sciences MDCT scanner (see Figure E2 in the online supplement).
Results were of similar or greater magnitude after adjusting for principal components of genetic ancestry and genetic risk score, initial FEV 1 percent predicted, and air pollution and other covariates (Table 3, Figure 2 ). Similar associations were demonstrated for incident airflow limitation, as defined by the prebronchodilator lower limit of normal (Table E1) . Effect estimates were also consistent when those participants with initial lung function measurements but missing follow-up measures were also included (Table E2) .
With respect to Pi10's component measures, greater AWT was positively correlated with Pi10 (r = 0.46; P , 0.001), showed a trend toward association with change in FEV 1 , and was significantly associated with incident COPD (Table 3) . Lumen diameter was negatively correlated with Pi10 (r = 20.06; P , 0.001), and greater lumen diameter was strongly protective with respect to incident COPD.
Incident CLRD Hospitalizations and Mortality
All 6,029 participants without prevalent CLRD were followed for hospitalization or ORIGINAL RESEARCH mortality due to CLRD for a median of 14.0 years and 78,147 person-years. By the end of follow-up, 84 participants had experienced a first hospitalization due or died of CLRD (1.4% cumulative incidence; incidence density rate, 10.75/10,000 person-years).
In fully adjusted models (Table 3) , each SD increment of Pi10 was associated with a 1.38-fold greater rate of first hospitalization or mortality due to CLRD (95% CI, 1.20-1.60; P , 0.001). The association between Pi10 and CLRD events appeared linear ( Figure 3 ) (P value for nonlinearity, 0.37).
Of first hospitalizations and mortality due to CLRD, 61 were attributed to COPD and 23 were attributed to asthma. In fully adjusted models, Pi10 was associated with COPD events (HR, 1.48/SD; 95% CI, 1.24-1.77; P , 0.001) but not asthma events (HR, 1.14/SD; P = 0.38).
Results were similar after adjusting for genetic risk and initial FEV 1 (Table 3) . There was no significant evidence for effect modification by smoking status, sociodemographics, or body habitus (P . 0.10 for multiplicative interaction terms ( Figure E1 ). In contrast to EBT scanners, associations were nonsignificant for participants scanned by MDCT, particularly Siemens scanners ( Figure E2 ). Results were similar in competing risks regression (Table E3 ). Both greater AWT and narrower lumen diameter were significantly associated with incident CLRD events ( Table 3) .
Discussion
Large airway dimensions on computed tomographic scans were associated with accelerated lung function decline and increased risk of incident spirometrydefined COPD and CLRD hospitalization and mortality, independent of initial lung function, in a large, prospective, populationbased sample free of lung disease at baseline. These prospective findings add to the growing literature which suggests that early changes in airway morphology predict risk of CLRD and that Pi10 and other CT measures of large airway dimensions may be suitable for the identification and characterization of individuals at increased risk of developing CLRD, particularly COPD. This is the first study, to our knowledge, to demonstrate associations of large airway wall dimensions with lung function decline and incident COPD and CLRD events in a general population-based sample of adults without clinical lung disease. Prior crosssectional work using high-risk smoking cohorts has linked increased Pi10 with increased respiratory symptoms (5, 6, 35, 36) , greater airflow limitation (37, 38) , greater bronchodilator responsiveness (39) , and decreased diffusing capacity (40) , in addition to greater exacerbation rate in the prior year (7). Greater Pi10 was also found to modify associations between percent emphysema and all-cause mortality in smokers (9) . Elevated Pi10 has recently been associated with a "symptomatic smoker" phenotype characterized by preserved lung function and an increased risk of Definition of abbreviations: BMI = body mass index; CT = computed tomography; EBT = electron beam computed tomography scanner; IQR = interquartile range; MDCT = multidetector computed tomography scanner; Pi10 = average wall thickness for a hypothetical airway of 10-mm lumen perimeter on computed tomography; SD = standard deviation. Numbers reported as mean (SD) or number (percent) unless otherwise noted. *Excludes all participants with prevalent chronic lower respiratory disease, defined as self-reported asthma or emphysema and/or inhaler use at study baseline. † Among ever smokers. ‡ Imatron EBT was used at three sites (Columbia, Northwestern University, and University of California, Los Angeles). Siemens MDCT was used at two sites (Johns Hopkins and University of Minnesota). GE Healthcare Life Sciences MDCT was used at one site (Wake Forest University).
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exacerbations (10) . Extending this finding, we observed an association in smokers between increased Pi10 and risk of first hospitalization or mortality due to CLRD. Pi10 is a composite measure of AWT and lumen diameter, which vary differentially in CLRD (11, 18) . Increased Pi10 may indicate greater AWT, narrowed lumina, or both. Indeed, in prior crosssectional work controlling for level within the airway tree hierarchy, we found that smokers with COPD demonstrated decreased AWT but even greater decreases in lumen; hence, Pi10 was higher (11) . These results were consistent with micro-CT results of explanted lungs in patients with COPD which suggested that small airway narrowing and disappearance were precursors to pathologic emphysema and airflow obstruction (41) . A recent study further supported this pathophysiology by showing that total airway count (TAC) on CT was decreased in COPD and associated with FEV 1 decline, as well as that "parent" airways proximal to missing "daughter" branches have both narrower lumina and thinner walls (42) . Although TAC was not available in our study, the strong associations in the present study between narrower airway lumina and increased risks of incident COPD and CLRD events are highly consistent with this literature. Furthermore, similar to recent findings associating TAC with lung function in never smokers (42) , our findings in healthy never and light smokers suggest the possibility that large airway measures may index developmental or early-life factors relevant to development of COPD (43, 44) .
By contrast, we note that our findings associating increased AWT with incident COPD and CLRD are discordant with recent evidence for thinner airway walls in COPD (11) . There are several possible explanations. First, increased AWT was seen in smokers (45) and may represent early injuries due to inflammation, remodeling, and/or chronic mucus hypersecretion; these early injuries may precede airway shrinkage and loss (46) along the length of the airway tree (11, 47) as clinical COPD develops and progresses. Indeed, increased AWT has been associated with self-reported chronic mucus hypersecretion (48) , which has been prospectively associated with accelerated lung function decline, incident COPD, and poor clinical outcomes (49) . Second, even if AWT is decreased in the majority of patients with smoking-related COPD, greater AWT may be associated with alternative CLRD subphenotypes, such as "symptomatic smokers" (10) and individuals with asthma (50) . Third, we were not able to spatially match the airway measures in this study, owing to the scanning protocol; hence, it remains possible that the findings for AWT may arise from differential sampling within the airway tree hierarchy (11) . We believe this sampling bias is unlikely in our study participants without clinical disease, though if present it would suggest that differential airway loss (41, 42) occurs in preclinical disease and can be detected using measures such as Pi10 derived from standard clinical scanners.
Strengths of the present work include a prospective design over 14 years of followup; a new approach to analysis of incident CLRD via clinical events in addition to spirometry-defined lung function; a clinically applicable, reliable measure of large airway dimensions on computed tomographic scans; adjustment for COPD genetic risk; and use of a highly characterized, 
population-based, epidemiologic cohort that included a large number of light smokers and never smokers-subgroups systematically excluded from most prior studies of COPD. Nonetheless, several limitations must be considered.
We used two-dimensional measures on images acquired on older low-dose CT scanners, which are less precise than threedimensional airway reconstructions on contemporary research CT scanners. Nonetheless, scan-rescan reproducibility for Pi10 on MESA baseline CT (ICC, 0.77-0.86) was similar to or better than that obtained with gold standard measures in SPIROMICS (Subpopulations and Intermediatae Outcomes in COPD Study; ICC, 0.79-0.82) (51), and, because threedimensional airway reconstructions may not be feasible on most clinical scans, the current approach may have greater potential clinical applicability. Upper lobe airways were not included, although MESA baseline computed tomographic scans included all lower lobe airways. Measures of hyperinflation were not available (52), nor were calculations of functional small airway disease, which require coregistration of inspiratory and expiratory computed tomographic scans (53) , but these are also not currently applicable to clinical scans.
Our results were consistent on EBT scanners, whereas subgroup analyses stratified by MDCT manufacturer yielded more heterogeneous results. Pi10 measurements derived from GE Healthcare Life Sciences MDCT scanners, which were lower on average, were not significantly associated with lung function, although they did associate with events. The converseassociations with lung function but not events-was observed for Siemens MDCT scanners. These findings could represent random error in the setting of small samples, given that they did not consistently support systematic measurement error or effect modification Results are per SD of log-transformed airway dimensions. For Pi10, these were equivalent on the logarithmic scale to 0.057 and 0.064 in the lung function and events analyses, respectively. For directly measured airway dimensions, these were equivalent to 0.37 and 0.13 for lumen diameter and AWT, respectively. ║ Models were adjusted for age, sex, race/ethnicity, height, and weight (partially adjusted), as well as for smoking status, pack-years, voxel size, computed tomography scanner type, and percent emphysema (fully adjusted). Height, weight, smoking status, and pack-years were time-varying covariates in the mixed models. The genetic risk-adjusted model is also adjusted for principal components of genetic ancestry (in the place of self-reported race/ethnicity) and COPD genetic risk score. The FEV 1 -adjusted model was additionally adjusted for the FEV 1 percent predicted at the initial spirometry examination. For analyses of annual change in FEV 1 , models adjusted for the genetic risk score and the initial FEV 1 were limited to 1,762. For analyses of incident COPD, models adjusted for the genetic risk score and the initial FEV 1 were limited to 1,652 (cases = 39). For analyses of CLRD hospitalization/mortality, models adjusted for the genetic risk score were limited to 5,631 (events = 76); models adjusted for the initial FEV 1 were further limited to 3,322 (events = 41). Directly measured airway dimensions were available in only a subset of participants with events follow-up, limiting the model to 5,626 (events = 72). Models using directly measured airway dimensions included both lumen diameter and AWT; results modeling these exposures separately yielded similar results.
by scanner type or manufacturer, although these possibilities could not be excluded. Spirometry was available for only a subset and was acquired after baseline, preventing us from excluding participants with subclinical airflow limitation at the time of CT. A substantial proportion of participants were excluded from lung function analyses because of incomplete follow-up; however, because higher Pi10 was associated with higher rates of censoring events (i.e., CLRD mortality), lung function results may be biased conservatively.
Clinical events, including mortality and exacerbations, were defined by administrative coding, which has potential for both overand underdiagnosis (54) . Nevertheless, our event definition was based on algorithms developed and validated in MESA (27, 28) . We defined events due to any CLRD as our primary outcome, because misclassification among CLRD is common and the degree of biological and clinical overlap between asthma and COPD remains controversial. Stronger associations with incident COPD versus asthma events were observed, but this may simply reflect a greater burden of incident COPD than of asthma in the middle-aged and older adults we studied.
Restricting our study to participants without clinical CLRD at baseline avoided biases related to potential medication effects and reverse causation, and it allowed us to interpret our events endpoint as an indicator of incident clinical disease. However, this limited the number of events, raising concerns regarding statistical power and potential overadjustment. Nonetheless, our results were similar and statistically significant in crude and sequentially adjusted analyses and were consistent with lung function results.
Incidence of airflow limitation and CLRD events was low in the participants included in this analysis, who were initially without airflow limitation and/or prevalent clinical CLRD. Notably, among MESA participants with prevalent Figure 2 . Stratified associations between average wall thickness for a hypothetical airway of 10-mm lumen perimeter on computed tomography (Pi10) and annual change in forced expiratory volume in 1 second (FEV 1 ) over five years of follow-up, with 95% confidence intervals, in participants without initial airflow limitation or prevalent clinical chronic lower respiratory disease. Fully adjusted models include age, sex, race/ethnicity, body mass index (BMI), smoking status, pack-years, percent emphysema, voxel size, and computed tomography (CT) scanner type. EBT = electron beam computed tomography; MDCT = multidetector computed tomography; PM 2.5 = particulate matter less than or equal to 2.5 mm in aerodynamic diameter; SD = standard deviation.
CLRD, the 5-year incidence of spirometrydefined COPD was 7%, which is not dissimilar to that in prior occupational and geriatric studies (55) (56) (57) , and the cumulative incidence of CLRD hospitalization/ mortality was 10%. MESA also excluded participants with clinical cardiovascular disease at baseline and is therefore healthier than the U.S. population average. MESA nevertheless represents the largest available resource to study associations between CT findings and CLRD in a healthy U.S. population-based sample.
In conclusion, greater Pi10 was associated with accelerated lung function decline, incident spirometrydefined COPD, and CLRD hospitalization and mortality in a general populationbased sample without clinical lung disease. This suggests that airway dimensions on CT may index environmental and developmental determinants of COPD or their interactions (44) beyond established risk factors. Although associations were relatively modest and may not be readily applicable to current clinical care, the question whether these measures could improve personalized risk assessment for CLRD and potentially identify and characterize early, preclinical COPD warrants further consideration. n ORIGINAL RESEARCH
